Absci Reports Q4 and FY25 Business Updates, Including Dosing of First Three Cohorts in Phase 1/2a HEADLINE Trial and Appoints Chief Medical Officer.

Absci Corporation has reported positive progress in its ABS-201 HEADLINE trial, with the first three cohorts dosed and favorable emerging safety data. The company has also unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates the follicle stem cell niche. Absci has appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer and has sufficient cash, cash equivalents, and marketable securities to fund operations into the first half of 2028.